Corcept Therapeutics Incorporated (BIT:1CORT)

Italy flag Italy · Delayed Price · Currency is EUR
73.18
-0.38 (-0.52%)
At close: Dec 5, 2025
15.50%
Market Cap 7.79B
Revenue (ttm) 631.70M
Net Income (ttm) 89.20M
Shares Out n/a
EPS (ttm) 0.74
PE Ratio 87.28
Forward PE 73.76
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 7
Open n/a
Previous Close 73.56
Day's Range n/a
52-Week Range 57.62 - 77.84
Beta n/a
RSI 66.71
Earnings Date Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 500
Stock Exchange Borsa Italiana
Ticker Symbol 1CORT
Full Company Profile

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD Financial Statements

News

There is no news available yet.